Newsletter February 2nd, 2019

Dear Foregen Supporters,

Welcome back to our most recent newsletter. We have some important updates for you, and an overview of the best parts of January.

What's Happened Since Last Time

  • We want to announce that our research proposal for animal trials has been submitted to the university for approval, and we should be hearing back from them soon!


  • Right now we're in contact with a few different media outlets and we hope that they might take interest in our project given our recent advances and more progress we’ll be making.


  • We received reports recently that links to our site were being spammed by bots.  However, we did not initiate or approve these efforts to spam links. This is a reminder that the unauthorized use of our name, such as using bots to spam people is not permitted.


  • From March 10-13th Foregen will be hosting a booth at SXSW!  We made valuable connections at the trade show last year and we hope that we can get even more interest with published scientific research to show this time around.


  • If you missed it from last time Eric Cunningham wrote a primer which summarizes the major points of our recent publication in Journal of Tissue Engineering.


  • For the month of January we reached a total of $9,190 in donations, which helps us move forward with the next parts of our mission!  Be sure to inform other activists, friends and family about Foregen and the science we’re pursuing to one day help provide genital integrity to men around the world. Our overall total to date is $412,589 - Let’s keep it up.


Tell Me Something Interesting

  • This piece describes a new 3D Bioprinter made as a result of collaboration between Prellis Biologics and Sweden based Cellink.  From the article: “Both companies will put together their expertise and funding in commercialising the first ultra-high resolution bioprinting system for microstructures such as vascular networks or capillaries.“


  • This article looks at a “Canadian not-for-profit organization Centre for Commercialization of Regenerative Medicine (CCRM) [which] focuses on developing and commercializing regenerative medicine technologies and cell and gene therapies. Since 2016, they have partnered with GE Healthcare to industrialize and scale those therapies.  [...] for example, the production of 36 billion pluripotent stem cells in a 10 L batch.”


Volunteer for Foregen

If you are interested in any of the following positions, please click on them to read more and apply:

Foregen Web Developers

Foregen Translators

Thanks for reading, and stay tuned for our next newsletter. If you’d like more frequent updates, please head over to our blog, or visit one of our social media accounts – the links are at the bottom of this newsletter.


The Foregen Team

Please check your e-mail for a link to activate your account.